• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Saniona

13.00 SEK

+1.01 %

Less than 1K followers

SANION

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+1.01 %
-4.27 %
-19.15 %
-38.68 %
-36.89 %
+29.48 %
+80.12 %
-16.50 %
+231.94 %

Saniona is a biotechnology company focused on developing treatments for neurological and psychiatric diseases. The company is researching new therapies that can improve patient outcomes and quality of life. The company operates globally with a primary presence in Europe and North America. Saniona was founded in 2011 and is headquartered in Denmark.

Read more
Market cap
1.79B SEK
Turnover
3.29M SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Research
Webcasts
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
27.8.
2026

Interim report Q2'26

26.11.
2026

Interim report Q3'26

25.2.
2027

Annual report '26

Press release23.06.2026 klo 10.44

Redeye: Saniona: Our take on the SAN2668 R&D day

Saniona
Press release11.06.2026 klo 10.10

BioStock: Three shots on goal: Saniona prepares to enter the clinic

Saniona
Press release04.06.2026 klo 09.00

Saniona to Host Virtual R&D Day Focusing on SAN2668 for Severe Pediatric Epilepsies

Saniona

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Press release28.05.2026 klo 19.36

Redeye: Saniona (Q1 Review): Setting up for the long run

Saniona
Regulatory press release27.05.2026 klo 18.15

Bulletin from the Saniona AB annual shareholders’ meeting on May 27, 2026

Saniona
Regulatory press release26.05.2026 klo 09.00

Saniona publishes its interim report for the first quarter of 2026

Saniona
Press release20.05.2026 klo 09.00

Invitation to Saniona Q1 investor call on 26 May 2026

Saniona
Regulatory press release30.04.2026 klo 14.05

Saniona publishes its Annual Report for 2025

Saniona
Regulatory press release24.04.2026 klo 18.35

Notice of Saniona AB annual shareholders’ meeting

Saniona
Saniona, Investor Day, Stockholm Corporate Finance Life Science Seminarium 2026
Webcast18.03.2026 klo 12.30

Saniona, Investor Day, Stockholm Corporate Finance Life Science Seminarium 2026

Saniona
Press release12.03.2026 klo 15.02

BioStock: Saniona enters clinical execution phase following transformational year

Saniona
Press release12.03.2026 klo 09.00

Meet Saniona at several conferences during the spring

Saniona
Press release03.03.2026 klo 11.47

Redeye: Saniona (Q4 review): Moving forward nicely

Saniona
Regulatory press release26.02.2026 klo 09.00

Saniona publishes its year-end report for 2025

Saniona
Press release20.02.2026 klo 09.00

Invitation to Saniona Q4 & year-end investor call on 26 February 2026

Saniona
Press release17.12.2025 klo 09.00

Saniona Bolsters Leadership Team to Accelerate Development of Key CNS Programs

Saniona
Press release01.12.2025 klo 14.21

BioStock: Saniona comments on major advancements during third quarter

Saniona
Press release28.11.2025 klo 12.44

Redeye: Saniona (Q3 Review) - Gearing up for clinical development

Saniona
Regulatory press release27.11.2025 klo 09.00

Saniona publishes its interim report for the third quarter of 2025

Saniona
Press release20.11.2025 klo 09.00

Invitation to Saniona Q3 investor call on 27 November 2025

Saniona